te in Parkinson's disease. Degeneration of these neurons is responsible for the major motor impairments of Parkinson's disease. CERE-120 is delivered by stereotactic injection to the terminal fields (i.e., the ends of the degenerating neurons), located in an area of the brain called the putamen, as well as the cell bodies for these same neurons, located in a different area of the brain, called the substantia nigra. Once CERE-120 is delivered to the brain, it provides stable, controlled and highly targeted neurturin expression for years following a single injection, confirmed in both animal and human studies.
About Parkinson's Disease
Parkinson's disease is a progressive movement disorder that affects a million people in the United States. Its main symptoms, stiffness, tremors and slowed movements and gait, are caused by a loss of dopamine-containing nerve cells in the substantia nigra, which project their axons to the putamen. Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements. There is currently no treatment that can reverse the degeneration of these neurons, let alone cure Parkinson's disease.
About CeregenePage: 1 2 3 4 5 Related biology technology :1
Ceregene, Inc. is a San Diego-based biotechnology company focused on the development of nervous system growth factors (neurotrophic factors) as treatments for neurodegenerative and retinal disorders using gene transfer for their delivery. The company has established a leadership position in the fields of gene therapy and neurotrophic factors, having launched 6 separate clinical trials in Parkinson's and Alzheimer's disease, enrolling a total of nearly 200 patients, over 100 of whom have been administered the gene therapy products, some several years ago, with no safety serious
. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs2
. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 20113
. Interleukin Genetics Reports Third Quarter 2011 Financial Results4
. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders5
. Nile Therapeutics Reports 2011 Third Quarter Financial Results6
. Pharmasset Reports Fiscal Year End 2011 Financial Results7
. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 20118
. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results9
. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy10
. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies11
. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results